References
- ResnikoffSPascoliniDEtya’aleDGlobal data on visual impairment in the year 2002Bull World Health Organ2004821184485115640920
- FriedmanDSO’ColmainBJMunozBPrevalence of age-related macular degeneration in the United StatesArch Ophthalmol2004122456457215078675
- Age-Related Eye Disease Study Research GroupA randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta-carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8Arch Ophthalmol2001119101417143611594942
- Age-Related Eye Disease Study 2 Research GroupLutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trialJAMA2013309192005201523644932
- OmennGSGoodmanGEThornquistMDEffects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular diseaseN Engl J Med199633418115011558602180
- SchwartzSGBrantleyMAJrPharmacogenetics and age-related macular degenerationJ Ophthalmol2011201125249
- HagstromSAYingGSPauerGJPharmacogenetics for genes associated with age-related macular degeneration in the Comparison of AMD Treatments Trials (CATT)Ophthalmology2013120359359923337555
- LoteryAJGibsonJCreeAJPharmacogenetic associations with vascular endothelial growth factor inhibition in participants with neovascular age-related macular degeneration in the IVAN studyOphthalmology2013120122637264324070809
- KleinMLFrancisPJRosnerBCFH and LOC387715/ARMS2 genotypes and treatment with antioxidants and zinc for age-related macular degenerationOphthalmology200811561019102518423869
- AwhCCLaneAMHawkenSZankeBKimIKCFH and ARMS2 genetic polymorphisms predict response to antioxidants and zinc in patients with age-related macular degenerationOphthalmology2013120112317232323972322
- ChewEYKleinMLClemonsTENo Clinically Significant Association between CFH and ARMS2 Genotypes and Response to Nutritional Supplements: AREDS Report Number 38Ophthalmology2014121112173218024974817
- AwhCCHawkenSZankeBWTreatment Response to Antioxidants and Zinc Based on CFH and ARMS2 Genetic Risk Allele Number in the Age-Related Eye Disease StudyOphthalmology2015122116216925200399
- ChewEYKleinMLClemonsTEAgronEAbecasisGRGenetic testing in persons with age-related macular degeneration and the use of the AREDS supplements: to test or not to test?Ophthalmology2015122121221525456150
- StoneEMGenetic testing for age-related macular degeneration: not indicated nowJAMA Ophthalmol Epub2015319
- GrobSLuoJHughesGGenetic analysis of simultaneous geographic atrophy and choroidal neovascularizationEye (Lond)20122681106111322699975
- SchwartzSGRe: Awh et al.: CFH and ARMS2 genetic polymorphisms predict response to antioxidants and zinc in patients with age-related macular degeneration (Ophthalmology 2013;120:2317–23)Ophthalmology20141218e3824793508
- WittesJMuschDCShould we test for genotype in deciding on Age-Related Eye Disease Study supplementation?Ophthalmology201512213525542537
- StoneEMAldaveAJDrackAVRecommendations for genetic testing of inherited eye diseases: report of the American Academy of Ophthalmology task force on genetic testingOphthalmology2012119112408241022944025